Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 4

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  liposomal irinotecan
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Cytostatic treatment with irinotecan liposomal in a patient with advanced pancreatic adenocarcinoma

100%
Będkowski P., Rogowski W.
OncoReview
|
2021
|
vol. 11
|
issue 2
40-43
EN
Pancreatic cancer is one of the most common malignant neoplasms with a short survival time and a low cure rate. This neoplasm progresses quickly, it is often diagnosed in the advanced stage, which means that systemic treatment regimens are not sufficiently effective. A case of 65-year-old patient with metastatic pancreatic cancer who underwent sequential chemotherapy with the use of liposomal irinotecan was presented.
2
Publication available in full text mode
Content available

Patient with disseminated malignant tumor of the pancreas. Application of liposomal irinotecan as a new option of palliative treatment

100%
Galińska B., Becht R.
OncoReview
|
2021
|
vol. 11
|
issue 3
73-76
EN
In palliative treatment of pancreatic neoplasms, chemotherapy regimens with gemcitabine, nab-paclitaxel, oxaliplatin, irinotecan, 5-fluorouracil or combinations of these drugs are used. The registration of liposomal irinotecan in the treatment of stage IV disease in patients with progression after gemcitabine creates new options for the treatment choice. The described case concerns a relatively young patient in whom the use of liposomal irinotecan in the registration indication turned out to be a safe and well-tolerated treatment.
3
Publication available in full text mode
Content available

Prolongation of survival time and improvement of the quality of life after treatment with irinotecan liposomal in the patient with metastatic pancreatic adenocarcinoma

100%
Rogowski W., Będkowski P.
OncoReview
|
2021
|
vol. 11
|
issue 3
77-79
EN
Pancreatic cancer is one of the malignant neoplasms with the worst prognosis. It is most often diagnosed at an advanced stage, which relates to unsatisfactory results of the therapy. Only about 15–20% of patients with pancreatic cancer qualify for surgery. The remaining patients are diagnosed with locally advanced disease or much more frequently in the generalized stage. Systemic treatment (chemotherapy) remains the mainstay of therapy in these patients, but both the response rate and progression-free time are unsatisfactory [1, 2]. This paper presents a case of a patient with metastatic pancreatic cancer, in whom three lines of systemic treatment were applied sequentially, which allowed to extend the survival time and improve the quality of life.
4
Publication available in full text mode
Content available

Metastatic pancreatic adenocarcinoma treated with liposomal irinotecan in combination with 5-fluorouracil and leucovorin as a II line chemotherapy

75%
Kraj L., Gryziak M., Żurawińska-Grzelka E., Woźniak K.
OncoReview
|
2021
|
vol. 11
|
issue 2
44-47
EN
The paper presents a case of a 54-year-old man with pancreatic tumor and intraperitoneal dissemination. The patient received treatment with gemcitabine in combination with nab-paclitaxel. After 18 months, the disease progressed, therefore the line of treatment was applied in the form of liposomal irinotecan with 5-FU/LV. This therapy provided progression-free survival for 7 months. The obtained results are better than the median progression-free survival obtained in the studies. This case demonstrates that liposomal irinotecan in the treatment of stage IV disease in patients progressing after gemcitabine opens up new treatment options.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.